We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amarin, FDA Reach Settlement in Suit Over Vascepa Promotion
Amarin, FDA Reach Settlement in Suit Over Vascepa Promotion
Amarin Pharmaceuticals will be able to promote its cholesterol drug Vascepa for off-label uses after resolving differences with the FDA in a free speech case involving off-label promotion of the capsules.